FeaturedProfiles.com: Featured Stocks, Featured Companies, Stock Picks, Stock Updates and Alerts

June 17, 2007

FeaturedProfiles.com Stock Pick: Novacea, Inc. (NOVC)

Price: $10.78 (long-term)

Novacea, Inc. is a biopharmaceutical company focused on in-licensing, developing and commercializing therapies for the treatment of cancer. The company's lead product candidate is Asentar, a promising prostate cancer drug currently in Phase III clinical trials for the treatment of glioblastoma multiforme.

NOVC recently ran to over $17.00 from the $7.00 level after the company announced a lucrative partnership deal with pharmaceutical giant, Schering-Plough. The deal is potentially worth $440 million to jointly develop Novacea's Asentar.

We expect further positive news out of NOVC. Considering the Schering-Plough deal, we believe NOVC is significantly undervalued down at a market cap of only around $50 million.

NOVC has a strong balance sheet with over $56 million in cash and short-term investments on the balance sheet as of March 31, 2007.

NOVC's chart has corrected from its high and is now beginning a new uptrend. __________________________________________________________________________________________








			June 17, 2007 FeaturedProfiles.com Stock Pick: Novacea, Inc. (NOVC) Price: $10.78 (long-term) Novacea, Inc. is a biopharmaceutical company focused on in-licensing, developing and commercializing therapies for the treatment of cancer. The company's lead product candidate is Asentar, a promising prostate cancer drug currently in Phase III clinical trials for the treatment of glioblastoma multiforme. NOVC recently ran to over $17.00 from the $7.00 level after the company announced a lucrative partnership deal with pharmaceutical giant, Schering-Plough. The deal is potentially worth $440 million to jointly develop Novacea's Asentar. We expect further positive news out of NOVC. Considering the Schering-Plough deal, we believe NOVC is significantly undervalued down at a market cap of only around $50 million. NOVC has a strong balance sheet with over $56 million in cash and short-term investments on the balance sheet as of March 31, 2007. NOVC's chart has corrected from its high and is now beginning a new uptrend. __________________________________________________________________________________________
			DISCLAIMER & RISK DISCLOSURE: FeaturedProfiles.com and SpeculatingStocks.com, Inc. and our affiliates ("our companies") are not registered investment advisers or broker/dealers. Our companies make no commitment that the purchase of securities of companies profiled or otherwise mentioned in our websites are suitable or advisable for any person or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the possible lack of liquidity for their securities, investing in such securities is highly speculative and carries a high degree of risk. Never invest based solely on information from this Web site or our email alerts. Our FeaturedProfiles.com Newsletter is our free alert email membership. We profile selected companies on our site. These companies compensate SpeculatingStocks.com, Inc. for profile coverage. This compensation can be found in the disclosure on the bottom of the page of profiles. This Disclaimer & Risk Disclosure is also at the bottom of profiles. Specific questions on membership or profiles can be obtained by writing the FeaturedProfiles.com at: staff@featuredprofiles.com.